Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Research

Mineralys Therapeutics
Regional / Research

Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision

November 12, 2026November 11, 2026 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat sustained a 17.8 mmHg reduction in systolic blood pressure through 48 weeks, providing additional long-term …

Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision Read More

Madrigal Pharmaceuticals
Regional / Research

Madrigal Reports Liver Improvements in Rezdiffra Studies

November 12, 2026November 11, 2026 - by Timothy Alexander

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) reported that up to 93% of patients taking its liver disease drug Rezdiffra experienced improved or stable liver stiffness measurements after approximately …

Madrigal Reports Liver Improvements in Rezdiffra Studies Read More
Latus Bio
Regional / Research

Latus Bio Reports Gene Delivery Gains in Brain, Kidney Studies

November 9, 2026November 9, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Latus Bio Inc. has reported preclinical advances in delivering gene therapies to brain and kidney cells, demonstrating improved targeting compared with conventional viral delivery technology as the …

Latus Bio Reports Gene Delivery Gains in Brain, Kidney Studies Read More

Mineralys Therapeutics
Regional / Research

Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial

November 3, 2026November 1, 2026 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat significantly reduced blood pressure and urinary protein levels in patients with chronic kidney disease, according …

Mineralys Drug Lowers Blood Pressure in Kidney Disease Trial Read More
Aclaris Therapeutics
Research

Aclaris Prioritizes Esophageal Drug Trial After Early Results

November 2, 2026November 1, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) plans to advance its experimental antibody ATI-052 into a Phase 2b trial for eosinophilic esophagitis in early 2027, concentrating development spending on …

Aclaris Prioritizes Esophageal Drug Trial After Early Results Read More

AstraZeneca
Regional / Research

AstraZeneca, Amgen Report Phase III Success for TEZSPIRE

October 29, 2026October 27, 2026 - by Timothy Alexander

WILMINGTON, DE — AstraZeneca and Amgen reported that their immunotherapy TEZSPIRE significantly reduced esophageal inflammation and swallowing difficulties in a Phase III clinical trial, strengthening the companies’ case for expanding …

AstraZeneca, Amgen Report Phase III Success for TEZSPIRE Read More
Johnson & Johnson
Regional / Research

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks

October 28, 2026October 26, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved fistula remission through 48 weeks in a Phase 3 clinical trial, …

J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks Read More

Annovis Bio
Research

Annovis Targets 2027 Alzheimer’s Drug Data Readout

October 28, 2026October 26, 2026 - by Timothy Alexander

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) will present updates on its experimental Alzheimer’s disease treatment buntanetap at a November medical conference in Boston as the Malvern-based biotechnology company …

Annovis Targets 2027 Alzheimer’s Drug Data Readout Read More
ArriVent BioPharma
Regional / Research

ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial

October 26, 2026October 25, 2026 - by Timothy Alexander

NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …

ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More
Teleflex Incorporated
Research

Teleflex Completes Enrollment in Coronary Scaffold Trial

October 24, 2026October 24, 2026 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has completed enrollment of 102 patients in a European clinical study evaluating longer versions of its dissolvable magnesium coronary scaffold, advancing research into …

Teleflex Completes Enrollment in Coronary Scaffold Trial Read More

Posts pagination

1 2 … 13 Next

Trending News

  • Woman Faces 10 Charges After Check Stolen From Mailbox

  • Gunpoint Robbery in Kennett Square Sparks Search for Suspect

  • Big Band Christmas Classics Come to West Chester’s Uptown

  • Overnight Theft Spree Hits Four North Coventry Neighborhood Streets

  • Holiday Stroll Brings Santa and Festive Fun to Yellow Springs

Subscribe for Updates

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Matylda Szydelko

Woman Faces 10 Charges After Check Stolen From Mailbox

November 17, 2026November 17, 2026

robbery suspect

Gunpoint Robbery in Kennett Square Sparks Search for Suspect

November 17, 2026November 16, 2026

Police News

Overnight Theft Spree Hits Four North Coventry Neighborhood Streets

November 16, 2026November 16, 2026

Copyright © 2026 MyChesCo.